OS Therapies Inc. - 10-Q Summary (Q2 2025)
Business Context and Reporting Period
Company: OS Therapies Inc. (OSTX)
Reporting Period: Quarter and six months ended June 30, 2025.
Business Overview: A clinical-stage biopharmaceutical company focused on developing treatments for Osteosarcoma and other solid tumors. The lead product candidate is OST-HER2, an immunotherapy. The company is currently conducting a Phase IIb clinical trial and has submitted a Breakthrough Therapy Designation request to the FDA.
Capital Structure: The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company. As of August 13, 2025, there were 31,891,933 shares of common stock outstanding.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(8,413,481) | $(3,016,472) |
| Loss per Share (Basic & Diluted) | $(0.35) | $(0.52) |
| Cash and Cash Equivalents (End of Period) | $2,802,013 | $94,925 |
| Net Cash Used in Operating Activities | $(5,802,138) | $(1,522,920) |
| Net Cash Provided by Financing Activities | $3,537,047 | $1,578,863 |
| Total Assets | $10,310,475 | $5,538,797 |
| Total Liabilities | $3,558,034 | $4,727,310 |
| Accumulated Deficit | $(46,845,856) | $(38,432,375) |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased significantly to $9.84 million for the six months ended June 30, 2025, compared to $1.41 million in the prior year period.
- Research & Development (R&D): Increased to $3.81 million (from $0.76 million) primarily due to vendor expenses for the Phase IIb clinical trial and IND-enabling studies.
- General & Administrative (G&A): Increased to $6.03 million (from $0.65 million) driven by marketing, investor relations, and advisory fees related to the PIPE financing and equity line of credit.
- Non-Cash Gains: The company recorded a gain of $1.42 million from the change in fair value of warrant liabilities, which reduced the net loss. This liability was fully reclassified to equity following stockholder approval in April 2025.
- Asset Acquisition: On April 9, 2025, the company acquired HER2 Assets (including ADXS-503 and ADXS-504 programs) from Ayala Pharmaceuticals for a total consideration of approximately $6.86 million (cash and stock). This resulted in the recognition of $6.75 million in Patents (Net) on the balance sheet.
- Debt Elimination: All convertible notes outstanding as of December 31, 2024, were converted to common stock during the IPO in August 2024. Consequently, interest expense dropped to $0 in 2025 compared to $1.61 million in the prior year period.
Guidance, Outlook, Risks, and Unusual Items
- Liquidity and Going Concern: The company has incurred net losses since inception and has negative operating cash flows. Management has raised substantial doubt about the company's ability to continue as a going concern. Operations are dependent on obtaining additional capital through public or private financing.
- Capital Raises:
- PIPE Financing: Raised approximately $7.1 million in late 2024/early 2025 via Series A Preferred Stock and Warrants.
- Warrant Inducement: Completed a warrant exercise inducement offer in July 2025, raising approximately $4.2 million in gross proceeds.
- Form S-3: Filed a registration statement on August 8, 2025, to offer up to $100 million in securities, including an at-the-market offering of up to $18 million.
- Regulatory Outlook: The company received positive feedback from the FDA regarding the Phase IIb trial design for OST-HER2. An End of Phase 2 meeting is anticipated in Q3 2025, with a potential Biologics License Application (BLA) submission following.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2025, due to a lack of segregation of duties and insufficient written policies.
- Legal Proceedings: The company is currently in arbitration regarding a claim for underwriter compensation from a former investment advisor, which management believes is meritless.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $2.8 million cash balance against the burn rate of ~$5.8 million per six months to confirm the timeline for the next capital raise.
- Going Concern Status: Review the specific terms and likelihood of success for the pending Form S-3 offering and other financing efforts to mitigate the "substantial doubt" disclosure.
- Internal Control Remediation: Assess the plan and timeline for remedying the material weakness in internal controls over financial reporting.
- Asset Acquisition Value: Evaluate the strategic value and amortization schedule of the $6.75 million patent asset acquired from Ayala Pharmaceuticals.
- Regulatory Milestones: Monitor the outcome of the anticipated Q3 2025 End of Phase 2 meeting with the FDA, which is critical for the BLA submission timeline.